Intent on shepherding more biopharma companies to market and keeping them growing, Prime Minister David Cameron recently unveiled a “Strategy for UK Life Sciences”. The strategy calls for the U.K. to launch a £180 million ($278.6 million) fund to push startup companies past the “valley of death,” a £130 million ($201.2 million) personalized medicine research fund, and a £50 million ($77.4 million) cell therapy technology center, among other components. The strategy also promises a new initiative to speed up approvals of new drugs. “We must ensure that the U.K. stays ahead,” Cameron said. Do you think the Strategy will help the U.K. reach its goals for biotechnology?

Poll Question:
How much do you think the new Strategy will succeed in enhancing the U.K.’s competitiveness in biopharma?

A great deal


Not much


Previous articleScientists Identify New Target for Apicomplexan Pathogens
Next articleMedicago Taps Cellectis to Boost Therapeutic Protein Production in Tobacco Plants